Literature DB >> 21537071

Emergence of multiple drug resistance Vibrio cholerae O1 in East Delhi.

Shukla Das1, Shilpee Choudhry, Rumpa Saha, Vishnampettai G Ramachandran, Kamaldeep Kaur, B L Sarkar.   

Abstract

INTRODUCTION: Considering the changing geographical and temporal occurrence of Vibrio cholerae, there is a continuing need to monitor the strain characteristics and antibiotic resistance patterns of this pathogen. The present study was conducted to document the changing biology of V. cholerae isolates in and around Delhi, India, and the development of antibiotic resistance.
METHODOLOGY: A total of 1,424 stool samples or rectal swabs from patients with acute secretory diarrhoea admitted to Guru Teg Bahadur Hospital, Delhi, between January 2007 and December 2009 were processed using standard bacteriological methods. Strains identified as V. cholerae were further subjected to serogrouping, phage typing and antimicrobial susceptibility testing. Minimum inhibitory concentration (MIC) of gentamicin and tetracycline was determined.
RESULTS: V. cholerae was isolated in 242/1,424 (17.0%) specimens. Of these, the majority were V. cholerae O1 serotype (98.3%) and serovar Ogawa. The drugs to which V. cholerae O1 isolates showed high levels of resistance were nalidixic acid, furazolidone, and cotrimoxazole throughout the study period, whereas strains were usually susceptible to chloramphenicol and cefotaxime. In 2007, there was a sudden increase of resistance to gentamicin and tetracycline, followed by a slow reversal to previous levels in subsequent years. The phage typing pattern (Basu and Mukherjee scheme) showed a dominance of phage type 2 throughout the study period.
CONCLUSION: The importance of reporting all cases of V. cholerae, should be greatly emphasized, with the ultimate goal of understanding the constantly changing resistance patterns of this pathogen.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537071     DOI: 10.3855/jidc.1251

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  7 in total

1.  What Happens When "Germs Don't Get Killed and They Attack Again and Again": Perceptions of Antimicrobial Resistance in the Context of Diarrheal Disease Treatment Among Laypersons and Health-Care Providers in Karachi, Pakistan.

Authors:  Heather A Joseph; Mubina Agboatwalla; Jacqueline Hurd; Kara Jacobs-Slifka; Adam Pitz; Anna Bowen
Journal:  Am J Trop Med Hyg       Date:  2016-05-02       Impact factor: 2.345

2.  Cholera.

Authors:  William Davis; Rupa Narra; Eric D Mintz
Journal:  Curr Epidemiol Rep       Date:  2018-07-27

3.  Multidrug resistant Vibrio cholerae O1 from clinical and environmental samples in Kathmandu city.

Authors:  Upendra Thapa Shrestha; Nabaraj Adhikari; Rojina Maharjan; Megha R Banjara; Komal R Rijal; Shital R Basnyat; Vishwanath P Agrawal
Journal:  BMC Infect Dis       Date:  2015-02-27       Impact factor: 3.090

4.  Cholera outbreak caused by drug resistant Vibrio cholerae serogroup O1 biotype ElTor serotype Ogawa in Nepal; a cross-sectional study.

Authors:  Pappu Kumar Gupta; Narayan Dutt Pant; Ramkrishna Bhandari; Padma Shrestha
Journal:  Antimicrob Resist Infect Control       Date:  2016-06-04       Impact factor: 4.887

5.  Antibiotics resistance in El Tor Vibrio cholerae 01 isolated during cholera outbreaks in Mozambique from 2012 to 2015.

Authors:  Liliana Candida Dengo-Baloi; Cynthia Amino Semá-Baltazar; Lena Vania Manhique; Jucunu Elias Chitio; Dorteia Luísa Inguane; José Paulo Langa
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

6.  Characterization of highly virulent multidrug resistant Vibrio cholerae isolated from a large cholera outbreak in Ghana.

Authors:  Patrick Kwame Feglo; Miriam Sewurah
Journal:  BMC Res Notes       Date:  2018-01-18

7.  Global status of tetracycline resistance among clinical isolates of Vibrio cholerae: a systematic review and meta-analysis.

Authors:  Mohammad Hossein Ahmadi
Journal:  Antimicrob Resist Infect Control       Date:  2021-08-06       Impact factor: 4.887

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.